Transdermal immunization: A recent tool for immunization by Dinesh, M et al.
 
 
 
 
 
 
w
w
w
.In
di
an
Jo
ur
na
ls
.c
om
   
   
 
 
 
 
 
 
M
em
be
rs
 C
op
y,
 N
ot
 fo
r C
om
m
er
ci
al
 S
al
e 
   
 
D
ow
nl
oa
de
d 
Fr
om
 IP
 - 
22
0.
22
5.
23
6.
59
 o
n 
da
te
d 
11
-J
un
-2
01
3
Research J. Pharm. and Tech. 3(4): Oct.-Dec. 2010 
 
 964
 
 
ISSN   0974-3618                     www.rjptonline.org                       
 
REVIEW ARTICLE 
 
Transdermal Immunization: A Recent Tool for Immunization 
 
Dinesh Mishra1, Anuja Mishra2, Vaibhav Dubey3 and Karunakar Shukla1 
1 Mahakal Institute of Pharmaceutical Studies, Ujjain (M.P.) India 
2 International Crops Research Institute for the Semi-Arid Tropics (ICRISAT), Hyderabad (A.P.) India 
3Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar (M.P.) India 
*Corresponding Author E-mail: dineshdops@yahoo.com 
 
ABSTRACT:  
Vaccination is one of the most powerful tools available in the ongoing battle against infectious agents. Virtually all 
recommended immunizations require parenteral administration, and many require a series of injections, therefore, new 
vaccine delivery methods, specifically alternatives to injections, are being sought. Transdermal immunization (TI) 
offers a new method for the delivery of vaccines, that relies on the application of antigen with adjuvant onto the outer 
layer of the skin and subsequent delivery to underlying Langerhans cells that serve as antigen-presenting cells. TI is a 
needle-free method of vaccine delivery that, will decrease the risk of needle-borne diseases, improve access to 
vaccination by eliminating the need for trained personnel and sterile equipment, and possibly provide a simple means 
for multivalent- or multiple boosting immunizations. This review presents various novel approaches for TI that is used 
alternative to parenteral immunizations. 
 
KEYWORDS: Transdermal immunization, Langerhans cells, Skin, Vaccination. 
 
INTRODUCTION: 
 Vaccination against infectious diseases is the major 
achievement of modern preventive medicine. The ultimate 
goal of vaccination is the stimulation of a specific immune 
response and the induction of a long-lasting immunologic 
memory to protect against subsequent disease1-2. Presently, 
most vaccines available are for intramuscular 
administration, which could be traumatic and their proper 
administration requires sterile technique, skilled and trained 
personnel. Thus, a needle free/non-invasive vaccination 
technique has become a global priority3. 
 
LIMITATIONS OF AVAILABLE VACCINE 
TECHNOLOGY: 
One of the major impediments to ensuring vaccine efficacy 
and compliance is that of delivery. Presently all 
recommended immunizations require parenteral 
administration and many require a series of injections. 
Although, injectable vaccines are effective and widely used 
yet they may have number of drawbacks: 1, 4-5 
• Pain associated with injection 
• Risk of accidental needle stick 
• Spread of disease, especially in developing countries 
due to reusing needles 
• Trauma, especially in infants 
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• Proper administration requires sterile technique, skill 
and trained personnel 
• Expense in administration and disposal 
• Stability and need of cold chain 
• High cost 
 
To make vaccine more economical and increasing 
compliance, vaccine should work after a single immunization 
using needle-free or non-invasive delivery systems. For 
optimal vaccination many factors can be considered such as: 
route of delivery, targeting of immune cell compartments and 
stimulation of humoral and cellular immunity6-7. 
 
There are several sites in which a vaccine can be 
administered including the muscle, mucosal surfaces and 
skin. Until the turn of century, the skin was thought to be 
impermeable. However, this view has changed and the 
progress achieved in this area clearly demonstrates that skin 
is a complex organ that may be one of the best sites for 
vaccination. Among the common routes of parenteral 
immunization, skin is the only site that shows potential as 
an immune organ. 
 
TRANSDERMAL IMMUNIZATION (TI): 
TI, a form of non-invasive vaccination involves the topical 
application of vaccine antigens to the skin that can elicit 
systemic antibody and T-cell responses. It is an innovative 
technique, having both practical and immunological merits 
requiring simple introduction of antigens to the host. The 
immunological implications of TI are potentially even more 
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profound, as this technique appears to target highly 
accessible antigen presenting cells (APCs) in the skin that 
can be exploited for a variety of immune outcomes8-9. It 
could turn out to be a highly promising and advantageous 
route for vaccination with a variety of antigens to induce 
potent and functional immune responses. Thus, this new 
method may significantly impact both the delivery of 
vaccines and open a new avenue for manipulation of the 
immune response10. 
 
The feasibility of TI with protein-based antigen was first 
demonstrated by Glenn4 et al. who used the term 
‘transcutaneous immunization (TCI). TCI was found to be 
aided by the use of adjuvant(s), such as cholera toxin (CT), 
heat-liable enterotoxin (ET) and their mutants which may 
induce potent immune responses when co-administered 
with antigen. Later on it was found that physical methods 
have limited success. Penetration enhancer reagents and 
topical adjuvants are not always desirable due to their 
toxicity. Thus, there is a need to develop new physical 
methods and topical adjuvants11. 
 
Advantages of TI 5 
 Target the antigen directly to the APCs of the skin 
 Reduce the amount of antigens required for the 
immunization 
 Sustained release 
 Reduce the frequency of administration 
 Patient compliance 
 Self-administration is possible 
 Eliminate accidental needle-stick 
 Non-invasive zero order delivery 
 Reduce the overall cost of immunization 
 
Mechanism of TI: 
The mechanisms involved in TI are yet to be fully 
characterized. The proposed hypothesis for the TI is the 
hydration of skin that allows superficial penetration of the 
stratum corneum (SC) by adjuvants. Throughout the 
epidermis, immune competent dendritic cells (DCs) called 
Langerhans cells (LCs), despite only composing 1% of the 
cell population, cover nearly 20% of the surface area 
through their horizontal orientation and long protrusions, 
which form a meshwork that allows them to uptake antigens 
that they encounter. LCs plays the chief role in the immune 
response to antigenic proteins in the skin. These cells 
phagocytose the antigen, and the adjuvants activate LCs, 
which then migrate to the draining lymph node where the 
antigen is presented to T-cells for the induction of an 
immune response (Fig. 1). During this process the LCs 
differentiate into DCs, which offer the antigen to naive 
CD4+ T-cells that have entered the lymph nodes through the 
high endothelial venules and finally initiate immune 
response5, 8. In addition to LCs, keratinocytes also play a 
role in the immunization process, which activated and 
synthesize a large number of cytokines involved in 
modulating the immune response and express intracellular 
adhesion molecules for various immune cells. In addition, 
the other two types of APCs in the skin (macrophages and 
lymphocytes) probably first require activation in order to 
present antigens and stimulate T-cells12,13. 
 
Fig. 1 Hypothesis for Transdermal immunization8 
 
TCI protocols appear to be particularly promising by 
gaining access to skin resident APCs, which are highly 
efficient for the initiation of humoral and/or cellular 
immune responses. Hence, skin has been shown to 
represent a quite diverse organ for the manipulation of the 
immune system.  Before the development of effective 
transdermal vaccination technique it is useful to review the 
structure and function of the skin. 
 
NOVEL APPROACHES FOR TI: 
Novel vaccine approaches comprised of various type of 
delivery systems and devices in order to deliver vaccines 
and target immune cell compartments of the skin. The 
various delivery devices consist of gene gun, jet injector, 
microneedles, microprojection arrays, electroporation, 
iontophoresis and sonophoresis etc. while delivery systems 
for effective vaccination are liposomes, modified 
liposomes, microcapsules, microparticles, nanoparticles, 
virus like particles etc.7. The ideal delivery systems/devices 
should be safe, non-toxic as well as non-immunogenic and 
also economical. It should be effective and reproducible for 
induction of proper immune responses against delivered 
antigen. Moreover such systems should be pharmaceutically 
acceptable, stable, biocompatible and amenable to patient. 
 
Delivery Devices: 
The skin is the most frequently used tissue for delivery 
devices due to the fact that it is easily accessible and 
monitored. Delivery device can be classified as instrument 
that uses brute force to deliver vaccine antigens through the 
SC into the skin. There are a wide range of delivery devices 
consisting of injection system, ballistics device as well as 
membrane de-stabilizers.  Some important delivery devices 
are discussed below: 
 
Gene gun: 
The gene gun is essentially a miniature shotgun where gold 
beads act as small projectiles carrying DNA through the 
skin into and around cells. Since a gene gun delivers 
plasmids directly into cells, this circumvents degradation of 
DNA, increasing the efficiency of gene transfer14. Because 
of this direct introduction of plasmid DNA into cells 
immune responses are generated by picograms of plasmid 
DNA15. Some limitations of the gene gun are that it may be 
used only for DNA and it is very unlikely that it could be 
used to deliver proteins. 
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Jet injection: 
Jet injection is a technique that uses air pressure to force 
liquid through the skin and around cells. One advantage 
with jet injectors is less tissue damage in comparison to 
conventional injection as the liquid follows the path of least 
resistance. This method has been used for intradermal, 
subcutaneous and intramuscular delivery of proteins as well 
as DNA16,17. 
 
Electroporation: 
Electroporation is a method to transiently permeabilize a 
membrane by the application of a single or multiple short 
duration pulses. Electroporation in vivo is accomplished by 
placing naked DNA on the skin, followed by placement of 
calipers on the skin and pulsing the skin with electrical 
charges. It is a technique that has been used for several 
years to deliver DNA into cells in vitro; recently it has been 
used in vivo 18,19. 
 
Iontophoration: 
It is similar to electroporation, uses weaker electric fields 
for a longer period of time than the strong fields used in 
electroporation20. Iontophoresis is an electrically-assisted 
drug delivery technology that enables non-invasive, 
controlled administration of low molecular weight peptide 
therapeutics21. 
 
Sonophoration: 
Sonophoration uses ultrasound waves to disorganize the SC 
lipids allowing the permeability of the skin to be increased. 
Several proteins such as insulin, IFN- and erythropoietin 
have been delivered through the skin in animal models. It is 
a relatively new technique that may be used for delivery of 
DNA and protein based vaccine antigens transdermally22-23. 
 
Photomechanical delivery: 
This technique uses a laser pulse to transiently increase 
permeability of skin. High molecular weight dextrans were 
delivered through the skin making the delivery of proteins 
and DNA possible with this technique24. 
 
Microfabricated microneedles: 
This technique has also been reported to overcome the 
barrier property of skin. These microneedles are 
approximately 150 µm long and create pathways across SC 
allowing transport of antigens. These are pointed 
projections fabricated into arrays that create conduits across 
the SC potentially allowing transport of DNA and proteins 
into the epidermis. Since these microneedles only penetrate 
through the SC and the viable epidermis, they do not reach 
nerve endings and are essentially painless25,26. 
 
Epidermal powder immunization (EPI): 
This technology delivers antigens on 1.5 to 2.5 µm gold 
particles to the epidermis using a needle free powder 
delivery system27. The powder is delivered with the help of 
disposable or multiple dose system (powderject) that 
employs high velocity stream of helium into the skin. DNA 
or protein adsorbed on gold particles and formulated in the 
form of powder is filled in the cartridge and inserted into 
the delivery device. The pressure of helium gas controls 
depth of penetration of vaccine28, 15. 
 
Delivery Systems: 
Various novel delivery systems have also been envisaged 
for safe and effective delivery of antigens thorough the 
skin. These delivery systems would provide controlled 
antigen release, immunoadjuvant properties and greater 
entrapment efficiency. The main delivery systems are 
discussed below: 
 
Miroparticles/Nanoparticles: 
Biodegradable micro/nanoparticles are suitable vehicles for 
delivery of the proteins and peptides to the APCs. These 
carriers offer numerous advantages like their potential 
ability for controlled release of encapsulated antigens and 
long lasting immune responses, efficient phagocytosis due 
to their particulate nature, and also capacity to induce TH1 
mediated cellular immune responses29. Various 
nanoparticles like gelatin, PLGA, chitosan, lipid 
microparticles have been used successfully for enhanced 
cellular uptake and induction of immune responses30-32. 
 
Liposomes: 
Liposomes are colloidal particles containing concentric 
bimolecular layers and possess ability to encapsulate both 
polar and non-polar drugs. These lipid vesicles are usually 
made up of phospholipids and cholesterol. They can be 
prepared of various size, number of lamellae, structure and 
of different payloads. They are a versatile tool for delivery 
of large array of bioactives ranging from drugs to high 
molecular weight proteins and peptides. The amphipathic 
nature of liposomes may allow them to be used widely as a 
non-invasive delivery agent for vaccine antigens33. 
 
Four general mechanisms of modulation of skin 
permeability via liposomal carriers have been reported34. 
These include a) intact drug-laden vesicle penetration into 
the different strata of the skin; b) liposomes acting as 
penetration enhancers via their skin lipid-fluidizing 
property; c) direct carrier–skin drug exchange by ‘collision 
complex transfer’ between the drug intercalated in the 
liposomal bilayer and the surface phase of the SC; and d) 
liposome-mediated enhanced transdermal drug delivery via 
appendegal pathways. 
 
However the results further obtained by various research 
groups about the effectiveness of liposomes for facilitating 
transdermal delivery were quite conflicting. The 
composition of the vesicles influences their physico-
chemical characteristics such as size, charge, 
thermodynamic phase, lamellarity and bilayer elasticity. 
Thus, by modifying the structure and composition of 
liposomes we can have more versatile, safe and efficient 
tool for topical immunization. Addition of the surfactant 
provides flexible or ultradeformable property to the 
conventional liposomes (elastic liposomes) while addition 
of ethanol leads to enhanced skin penetration (ethosomes). 
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Elastic liposomes: 
A novel class of modified liposome, containing an optimum 
amount of edge activator and providing it with a highly 
elastic nature, has been developed Transfersome® 
(http://IDEA AG-Science.htm). These carriers were first 
described by Cevc and Blume35 (1992), and subsequently 
they have been the subject of numerous patents and 
literature reports. 
 
Elastic liposomes (Transfersome®) are specially optimized, 
ultradeformable lipid supramolecular aggregates that have 
been claimed to penetrate and permeate the skin layers as 
intact vesicles to reach the systemic circulation. The 
elasticity possessed by these vesicles is the consequence of 
an edge activator (often a single-chain surfactant that 
enhances the deformability via lipid bilayer destabilization) 
incorporated within the phospholipid-based system. In most 
cases, the phospholipid and edge activator contents have 
been optimized to attain the desired deformable nature of 
the elastic liposomes, to increase elasticity and 
penetrability. These novel carriers are applied in the form of 
semi-dilute suspension, without occlusion and offer the 
efficient dermal and transcutaneous drug delivery of the 
high and low molecular weight substances36-37. 
 
Traditional liposomes are typically 100-400 nm in diameter 
and have a rigid structure. These are too large to fit within 
the intercellular lipid domains of the SC and to penetrate to 
the deeper layers of the epidermis. Due to the flexibility 
conferred on the vesicles by the surfactant molecules, 
elastic liposomes are claimed to be able to squeeze through 
channels one tenth of its diameter38. 
 
In the present context, a number of Transfersome® based 
products are at an advanced clinical trial stage, such as 
IDEA-03339, which is expected to become the first truly 
effective topical analgesic for the effective management of 
osteoarthritis. 
 
Salient features of elastic liposomes: 
• Elastic liposomes can accommodate hydrophobic 
as well as hydrophilic moieties due to its infrastructure. 
• Due to their deformable nature they can squeeze 
through narrow constriction without measurable loss and 
give better penetration of intact vesicles. 
• They can act as a carrier for low as well as high 
molecular weight substances e.g. analgesic, anesthetic, 
corticosteroids, sex hormone, anticancer, insulin, gap 
junction protein, and albumin. 
• They are made up of natural phospholipids hence 
are biocompatible and biodegradable. 
• They have higher entrapment efficiency. 
• They protect the encapsulated moieties from 
metabolic degradation. 
• They act as depot hence release their contents 
slowly and gradually. 
• They can be used for both systemic and topical 
delivery. 
• They are easy to scale up. 
Mechanism of modulation of skin permeability by elastic 
liposomes 
Several studies investigated possible mechanisms by which 
elastic vesicles could improve skin delivery of drugs. Two 
mechanisms were proposed40-42. First, vesicles can act as 
drug carrier systems, whereby intact vesicles enter the SC 
carrying vesicle-bound drug molecules into the skin 
(mechanism 1). Second, vesicles can act as penetration 
enhancers, whereby vesicle bilayers enter the SC and 
subsequently modify the intercellular lipid lamellae. This 
will facilitate penetration of free drug molecules into and 
across the SC (mechanism 2). 
 
The first mechanism was put forward by Cevc et al. for 
elastic liposomes35,43,44. They proposed that the driving 
force for the vesicles entering the skin is xerophobia (the 
tendency to avoid dry surroundings). The important 
difference between deformable liposomes and traditional 
liposomes is the high and stress-dependent adaptability of 
such deformable vesicles, which enables them alone to 
squeeze between the cells in the SC, despite the large 
average vesicle size. Thus, they can trespass the intact skin 
spontaneously, under the influence of the naturally 
occurring, in vivo transcutaneous hydration gradient, intact 
without permanent disintegration. Using confocal laser 
scanning microscopy (CLSM), Schatzlein and Cevc45 
further reported highly fluorescent interclusters and 
intercorneocyte pathways located within the intercellular 
lipid lamella of murine SC, which, according to them, could 
further act as virtual channels through which intact vesicles 
could penetrate. 
 
A study by Verma46 et al. utilising a CLSM technique, 
demonstrated that vesicular size greatly affects the 
transdermal potential of the prepared vesicular system. 
Their study indicated that larger vesicles (size  600 nm) 
were not able to deliver their contents into the deeper layers 
of the skin. These vesicles stay in/on the SC, and after 
drying they may form a layer of lipid, which may further 
strengthen the barrier property of the SC. Liposomes with a 
size  300 nm were able to deliver to some extent into the 
deeper layers of the skin. However, liposomes with size a  
70 nm seemed to achieve the maximum depth. The exact 
mechanism of skin modulation by intact vesicle penetration 
is just a speculation that needs experimental corroboration. 
 
When a suspension of Transfersome® vesicles is placed on 
the surface of the skin, the water evaporates from the skin 
surface and the vesicles start to dry out. Due to the strong 
hydrophilicity of major Transfersome® ingredients, the 
vesicles are attracted to the areas of higher water content in 
the narrow gaps between adjoining cells in the skin. The 
phenomenon, together with the vesicle's extreme ability to 
deform, enables each Transfersome® to temporarily open 
the pores through which water normally evaporates between 
the cells. This creates 20-30 nm wide pathways between the 
skin cells, two orders of magnitude wider than the original 
nanopores. Such newly activated inter-cellular passages can 
accommodate sufficiently deformable vesicles maintaining 
their integrity but changing their shape to fit the channel; 
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the calculated sequence in the above illustration highlights 
the process. Insufficiently deformable entities fail to pass 
through the channels. Along these said pathways in the 
horny layer, a Transfersome® reaches regions of high water 
content in the deeper skin layers. Subsequently, the vesicles 
that have crossed the skin barrier are distributed between 
the cells. Being too large to enter the blood vessels locally, 
a Transfersome® bypasses the cutaneous capillary bed and 
reaches the subcutaneous tissue. Ultimately, the vesicle may 
arrive into the systemic blood circulation via the fenestrated 
lymphatic system, which has openings (fenestrations) of 
sufficient width; most often, however, the vesicles applied 
locally are ultimately bio-processed and their building 
blocks are re-utilised in peripheral tissues below the 
application site47. 
 
Ethosomes: 
Ethanolic liposomes or ethosomes are novel lipid based, 
non-invasive delivery carriers that enable biologically 
active agents to reach the deep skin layer and/or systemic 
circulation. These systems are mainly composed of 
phospholipids, a relatively high concentration of ethanol 
(20-50%) and water37,42. Previously it was generally thought 
that a high alcohol concentration lead to the destruction of 
lipid vesicular structure, owing to the interdigitating effect 
of alcohol on lipids. Later on Touitou48 et al. demonstrated 
the coexistence of phospholipid vesicles with a high 
concentration of ethanol, leading to the formation of soft, 
malleable, highly fluid vesicles (ethosomes). They 
demonstrated the formation of vesicles using31P-NMR and 
paramagnetic ion NMR experiments. 
 
Salient features of ethosomes 
• Ethosomes provide a mode for passive non-
invasive delivery. 
• These carriers are suitable for hydrophilic, 
lipophilic molecules, peptides and other macromolecules. 
• They can act as a carrier for low as well as high 
molecular weight substances e.g. analgesic, corticosteroids, 
sex hormone, insulin etc. 
• They are biocompatible and biodegradable. 
• Due to high ethanol content possess high 
entrapment efficiency. 
• They possess high cell transfection efficiency. 
• They may act as depot formulation hence 
sustained release is obtained. 
• They can be applicable for topical as well as 
systemic delivery. 
• Easy to scale up, as procedure is simple, does not 
involve lengthy procedure and unnecessary use of 
pharmaceutically unacceptable additives. 
Mechanism of penetration of ethosomes 
Ethanol is a well-known penetration enhancer and is 
commonly believed to act by affecting the intercellular 
region of the SC, thus enhancing permeation. This 
penetration enhancing effect of ethanol could be attributed 
to two factors: i) an increase in thermodynamic activity due 
to the evaporation of ethanol, known as ‘push effect’; and 
ii) ‘pull effect’, in which the penetration of a drug molecule 
is increased due to a reduction by ethanol in the barrier 
property of the SC49. Ethanol encapsulated in lipid vesicles 
in the form of ethosomes provides fluidity to the ethosomal 
bilayers, and, when applied to the skin, it fluidizes the SC 
lipids and well demonstrated by differential scanning 
calorimetry37. 
 
In terms of the enhanced potential for the transdermal 
delivery of biologically active agents in ethosomal carriers, 
the exact mechanism of skin permeability modulation 
remains speculation. According to Touitou50 et al. a 
synergistic mechanism between ethanol, vesicles and skin 
lipids exists, leading to an improved permeation profile. 
The proposed mechanism of ethosomal skin modulation lies 
in the interaction of ethanol with lipid molecules in the 
polar head group region, resulting in a reduction in the 
transition temperature (Tm) of SC lipids, thus enhancing 
their fluidity, leading to a disordered SC, which provides a 
potential site for soft, malleable ethosomes to penetrate 
more easily within the skin layers. 
 
CONCLUSION: 
TI is an innovative investigational technology, which 
promises to be an efficient and cost-effective means of 
immunizing patients. It not only allows ease of 
administration of vaccines, but may also elicit more potent 
immune responses than conventional needle injection given 
in equivalent doses due to the immunocompetence of 
epidermis along the skin border. Amongst various 
approaches for non-invasive immunization, vesicular 
approach is gaining wide acceptance for topical delivery. 
This is because they can act as carrier as well as exhibit 
adjuvant action, which help in boosting of the immune 
responses. The vesicular carriers including Elastic 
liposomes, Liposomes, Niosomes, Ethosomes etc. require 
no specially trained personnel and may avoid risk 
associated with needle prick. These carrier systems are 
intended to avoid the risks and complications associated 
with percutaneous delivery of vaccines (needles), to 
eliminate apprehension and pain associated with 
immunization, and to avoid the complications of reuse of 
disposable syringes and needles. It can be genuine approach 
by which discomfort related to all other routes such as 
cellular toxicity in case of intramuscular injection and 
degradation of antigen by oral route can be avoided. 
 
REFERENCES: 
1. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization 
made possible by cholera toxin. Nature 1998; 391:851. 
2. Foged C, Sundblad A, Hovgaard L. Targeting vaccines to 
dendritic cells. Pharm Res 2002; 19(3):229–38. 
3. Mishra D, Dubey V, Asthana A, Saraf DK, Jain NK. Elastic 
liposomes mediated transcutaneous immunization against 
hepatitis B. Vaccine 2006; 24:4847-55. 
4. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, 
Alving CR. Cutting edge: transcutaneous immunization with 
cholera toxin protects mice against lethal mucosal toxin 
challenge. J Immunol 1998; 161:3211-3214. 
5. Hammond SA, Tsonis C, Sellins K, Rushlow K, Scharton-
Kersten T, Colditz I, Glenn GM. Transcutaneous immunization 
of domestic animals: opportunities and challenges. Adv Drug Del 
Rev 2000; 43:45-55. 
 
 
 
 
 
 
w
w
w
.In
di
an
Jo
ur
na
ls
.c
om
   
   
 
 
 
 
 
 
M
em
be
rs
 C
op
y,
 N
ot
 fo
r C
om
m
er
ci
al
 S
al
e 
   
 
D
ow
nl
oa
de
d 
Fr
om
 IP
 - 
22
0.
22
5.
23
6.
59
 o
n 
da
te
d 
11
-J
un
-2
01
3
Research J. Pharm. and Tech. 3(4): Oct.-Dec. 2010 
 
 969
6. Babiuk LA. Broadening the approaches to developing more 
effective vaccines. Vaccine 1999; 17:1587-1595. 
7. Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. 
Cutaneous vaccination: the skin as an immunologically active 
tissue and the challenge of antigen delivery. J Control Rel 2000; 
66:199-214. 
8. Glenn GM, Scharton-Kersten T, Alving CR. Advances in vaccine 
delivery: transcutaneous immunization. Exp Opin Invest Drugs 
1999a;8(6):797-805. 
9. Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, 
Alving CR. Principles of transcutaneous immunization using 
cholera toxin as an adjuvant. Vaccine 1999; 17:S37-S43. 
10. Warger T, Schild H, Rechtsteiner G. Initiation of adaptive 
immune responses by transcutaneous immunization. Immunol 
Lett 2007; 109:13-20. 
11. Upadhyay P. Enhanced transdermal-immunization with diptheria-
toxoid using local hyperthermia. Vaccine 2006; 24:5593-5598. 
12. Bos JD, editor. Skin immune system. USA: CRC press, 1990. p. 
57-87, 257-291. 
13. Gaspari AA, Jenkins MR, Katz SI. Induction of in vivo 
hyporesponsiveness to contact allergens by hapten-modified Ia+ 
keratinocytes. J Immunol 1991; 147:4155-4161. 
14. Peachman KK, Rao M, Alving CR. Immunization with DNA 
through the skin. Methods 2003; 31:232-242. 
15. O’Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine 
delivery. Adv Drug Del Rev 2006; 58:29-51. 
16. Mumper RJ, Cui Z. Genetic immunization by jet injection of 
targeted pDNA-coated nanoparticles. Methods 2003; 31:255-262. 
17. Rao SS, Gomez P, Mascola JR, Dang V, Krivulka GR, Yu F, 
Lord CI, Shen L, Bailer R, Nabel GJ, Letvin NL. Comparative 
evaluation of three different intramuscular delivery methods for 
DNA immunization in a nonhuman primate animal model. 
Vaccine 2006; 24:367-373. 
18. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted 
DNA vaccine delivery using electroporation in rabbits I: efficacy. 
Int J Pharm 2005; 294:53-63. 
19. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. 
Induction of cytotoxic T-lymphocytes by electroporation 
enhanced needle-free skin immunization. Vaccine 2006; 24:1282-
1290. 
20. Oldenburg KR, Vo KT, Smith GA, Selick HE. Iontophoretic 
delivery of oligonucleotides across full thickness hairless mouse 
skin. J Pharm Sci 1995; 84:915-921. 
21. Schuetz YB, Schuetza,b, Carrupt P, Naik A, Guy RH, Kalia YN. 
Structure–permeation relationships for the non-invasive 
transdermal delivery of cationic peptides by iontophoresis.  Eur J 
Pharm Sci 2006; 29:53-59. 
22. Mitragotri S, Edwards DA, Blankschtein D, Langer R. A 
mechanistic study of ultrasonically enhanced transdermal drug 
delivery. J Pharm Sci 1995; 84:697-706. 
23. Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency 
ultrasound as a transcutaneous immunization adjuvant. Vaccine 
2005; 23:3800-3807. 
24. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. 
Photomechanical transcutaneous delivery of macromolecules. J 
Invest Dermatol 1998; 111:925-29. 
25. Park J, Allen MG, Prausnitz MR. Biodegradable polymer 
microneedles: fabrication, mechanics and transdermal drug 
delivery. J Control Rel 2005; 104:51-66. 
26. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv 
Drug Del Rev 2006; 58:68-89. 
27. Chen D, Erickson CA, Endres RL, Periwal SB, Chu Q, Shu C, 
Maa YF, Payne LG. Adjuvantation of epidermal powder 
immunization. Vaccine 2001; 19:2908-2917. 
28. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated 
approaches for delivery of DNA and protein vaccines into the 
epidermis. Comparative Immunol Microbiol Infect Disease 2003; 
26:373-388. 
29. Wischke C, Borchert H, Zimmermann J, Siebenbrodt I, Lorenzen 
DR. Stable cationic microparticles for enhanced model antigen 
delivery to dendritic cells. J Control Rel 2006; 114:359–368. 
30. Christine-Lutsiak ME, Robinson DR, Coester C, Kwon GS, 
Samuel J. Analysis of poly (d, l-lactic-co-glycolic acid) 
nanosphere uptake by human dendritic cells and macrophages in 
vitro. Pharm Res 2002; 19(10):1480-1487. 
31. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin 
nanoparticles by murine dendritic cells and their intracellular 
localization. Eur J Pharm Biopharm 2006; 62:306–314. 
32. Saraf S, Mishra D, Asthana A, Jain R, Singh  S, Jain NK. Lipid 
microparticles for mucosal immunization against hepatitis B. 
Vaccine 2006; 24:45-56. 
33. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for 
transdermal and dermal delivery. Drug Discovery Today 2005; 
2(1):67-74. 
34. El Maghraby GM, Williams AC, Barry BW. Can drug-bearing 
liposomes can penetrate intact skin. J Pharm Pharmacol 2006; 
58:415-429. 
35. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing 
to the transdermal osmotic gradients and hydration force. 
Biochim Biophys Acta 1992; 1104:226-232. 
36. Benson HAE. Transfersomes for transdermal drug delivery. Exp 
Opin Drug Del 2006; 3(6):727-737. 
37. Dubey D, Mishra D, Nahar M, Jain NK. Vesicles as tools for the 
modulation of skin permeability. Expert Opin Drug Deliv 2007a; 
4(6):579-593. 
38. Cevc G. Transfersomes, liposomes and other lipid suspension on 
the skin: permeation enhancement, vesicle penetration, and 
transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996; 
13(3-4):257-388. 
39. Idea AG: US6165500 (2000). 
40. Honeywell-Nguyen PL, Arenja S, Bouwstra JA. Skin penetration 
and mechanisms of action in the delivery of the D2-agonist 
rotigotine from surfactant-based elastic vesicle formulations. 
Pharm Res 2003a; 20:1619–1625. 
41. Honeywell-Nguyen, PL, Wouter Groenink HW, de Graaff AM, 
Bouwstra JA. The in vivo transport of elastic vesicles into human 
skin: effects of occlusion, volume and duration of application. J 
Control Rel 2003b; 90:243–255. 
42. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. 
Lipid vesicles for skin delivery of drugs: reviewing three decades 
of research. Int J Pharm 2007; 332:1–16. 
43. Cevc G, Blume G. New, highly efficient formulation of 
diclofenac for the topical, transdermal administration in 
ultradeformable drug carriers, transfersomes. Biochim Biophys 
Acta 2001; 1514:191–205. 
44. Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid 
vesicles can penetrate the skin and other semi-permeable barriers 
unfragmented: evidence from double label CLSM experiments 
and direct size measurements. Biochim Biophys Acta 2002; 
1564:21–30. 
45. Schatzlein A, Cevc G. Non-uniform cellular packing of the 
stratum corneum and permeability barrier function of intact skin: 
a high-resolution confocal laser scanning microscopy study using 
highly deformable vesicles (transfersomes). Br J Dermatol 1998; 
138(4):583-592. 
46. Verma DD, Verma S, Blume G, Fahr A. Particle size of 
liposomes influences dermal delivery of substances into skin. Int 
J Pharm 2003; 258(1-2):141-151. 
47. http://IDEA AG-Science.htm 
48. Touitou E, Alkabes M, Dayan N. Ethosomes: novel lipid 
vesicular system for enhanced delivery. Pharm Res 1997; 
S14:305-306. 
49. Kadir R, Stempler D, Liron Z, Cohen S. Delivery of theophylline 
into excised human skin from alkanoic acid solutions: a push–
pull mechanism. J Pharm Sci 1987; 76(10):774-79. 
50. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes- 
novel vesicular carriers for enhanced delivery: characterization 
and skin penetration properties. J Control Rel 2000; 65:403–418. 
 
